Loading...
The theory that inflammation plays a primary role in the pathogenesis of Alzheimer disease (AD) has led to speculation that anti-inflammatory agents may be a fruitful area of research. We now have results from two randomized, double-blind, controlled studies of three different anti-inflammatory agents for the prevention of cognitive loss associated with age.
In the first study, investigators for the AD Anti-inflammatory Prevention Trial (ADAPT) compared 400 mg of celecoxib, 440 mg of naproxen, and placebo in 2125 individuals aged 70 or older who had a family history of AD. The study was terminated prematurely because of concerns about the safety of celecoxib; at that time, the rates of diagnosis of dementia did not differ significantly among…